Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer
    Meeting Abstract

    Elkrief, A.; Bowman, A.; Rizvi, H.; Hellmann, M.; Riely, G. J.; Schoenfeld, A. J.; Ladanyi, M.; Vanderbilt, C. M.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
    Meeting Abstract

    Chesney, J.; Wise-Draper, T.; Sarnaik, A. A.; Finckenstein, F. G.; Hari, P.; Jagasia, M.; Desai, A.; Suzuki, A.; Wu, X.; Warner, A. B.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma
    Meeting Abstract

    Sato, T.; Ikeguchi, A. P.; Nathan, P.; Carvajal, R. D.; Shoushtari, A. N.; Gajewski, T. F.; Hassel, J. C.; Rioth, M.; Leyvraz, S.; Daniels, G. A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma
    Meeting Abstract

    Schlaak, M.; Dummer, R.; Kirkwood, J. M.; Joshua, A.; Milhem, M.; Gastaud, L.; Mauch, C.; Yushak, M. L.; Lockwood, S.; Hayes, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma
    Meeting Abstract

    Piulats Rodriguez, J. M.; Piperno-Neumann, S.; Rutkowski, P.; Nathan, P.; Hassel, J. C.; Espinosa, E.; de la Cruz Merino, L.; Ochsenreither, S.; Shoushtari, A. N.; Orloff, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • VITALIZE: A phase IIb, open-label, multicenter, randomized parallel-group, two-stage, study of maveropepimut-S, pembrolizumab, with or without intermittent low-dose cyclophosphamide, in r/r DLBCL
    Meeting Abstract

    Matasar, M.; Teti, J.; Mody, K.; Fiset, S.; Graff, J.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety
    Meeting Abstract

    Gonzalez Martin, A. J.; Pothuri, B.; Vergote, I. B.; Graybill, W.; Mirza, M. R.; Mccormick, C.; Lorusso, D.; Freyer, G.; Backes, F.; Baumann, K. H.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis
    Meeting Abstract

    Van Nieuwenhuysen, E.; O'Malley, D.; O'Cearbhaill, R. E.; Moore, K. N.; Hamilton, E. P.; Yeku, O.; Bouberhan, S.; Hou, J. Y.; Yoo, S. Y.; Brouwer-Visser, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • MAJIC: A phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Review

    Ryan, C. E.; Davids, M. S.; Hermann, R.; Shahkarami, M.; Biondo, J.; Abhyankar, S.; Alhasani, H.; Sharman, J. P.; Mato, A. R.; Roeker, L. E.
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save